secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001437749-25-024956
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica CMO Lorianne Masuoka resigns; Julie Krop appointed as successor
-------------------------------------------------------------------------

- Lorianne Masuoka resigned as CMO effective Aug 4, 2025 for personal reasons; separation agreement provides health benefits through Oct 2026.
- Julie Krop appointed as CMO effective Aug 11, 2025; Krop brings 20+ years experience, most recently CMO at PureTech Health.
- Krop previously CMO at Freeline Therapeutics and AMAG Pharmaceuticals; involved in preeclampsia drug development at AMAG.
- Krop will lead clinical development of DM199 for preeclampsia and acute ischemic stroke.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925024956/0001437749-25-024956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925024956/dmtp20250805_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-024956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer